IO Biotech, Inc. Overview
Pro stress-test →IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead candidate, Cylembio (IO102-IO103), demonstrated clinical improvement in progression-free survival in a Phase 3 trial for advanced melanoma, though it narrowly missed statistical significance versus pembrolizumab monotherapy.
Strategic Profile
Pro stress-test →The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. The company has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, positioning it as a leader in next-generation cancer immunotherapy with a differentiated dual-targeting mechanism.
Competitive Landscape
Pro stress-test →IO Biotech's lead candidate targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). The company competes in the crowded immuno-oncology space with established players like Merck (Keytruda), Bristol Myers Squibb, and Roche, as well as emerging cancer vaccine developers such as BioNTech and CureVac. IO Biotech's differentiation lies in its dual-targeting T-win platform, though commercial viability remains unproven following the Phase 3 setback.
Industry Context
IO Biotech, Inc. operates in Biopharmaceutical/Immuno-Oncology.
Key facts
Founded: 2014 · Headquarters: Copenhagen, Denmark · Employees: 78-80 · Revenue: $35M (as of May 2025) · Market cap: $23.21M